Current and Emerging Applications of Liquid Biopsy in Pan-cancer

Overview

Journal Transl Oncol

Specialty Oncology

Date 2023 Jun 14

PMID 37315508

Authors

Wenxiang Wang

Yue He

Fan Yang

Kezhong Chen

Affiliations

Soon will be listed here.

Abstract

Cancer morbidity and mortality are growing rapidly worldwide and it is urgent to develop a convenient and effective method that can identify cancer patients at an early stage and predict treatment outcomes. As a minimally invasive and reproducible tool, liquid biopsy (LB) offers the opportunity to detect, analyze and monitor cancer in any body fluids including blood, complementing the limitations of tissue biopsy. In liquid biopsy, circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) are the two most common biomarkers, displaying great potential in the clinical application of pan-cancer. In this review, we expound the samples, targets, and newest techniques in liquid biopsy and summarize current clinical applications in several specific cancers. Besides, we put forward a bright prospect for further exploring the emerging application of liquid biopsy in the field of pan-cancer precision medicine.

Citing Articles

Prospective validation study: a non-invasive circulating tumor DNA-based assay for simultaneous early detection of multiple cancers in asymptomatic adults.

Nguyen L, Nguyen T, Le V, Bui V, Nguyen L, Pham N BMC Med. 2025; 23(1):90.

PMID: 39948555 PMC: 11827191. DOI: 10.1186/s12916-025-03929-y.

Different efficacy of tyrosine kinase inhibitors by KIT and PGFRA mutations identified in circulating tumor DNA for the treatment of refractory gastrointestinal stromal tumors.

Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N BJC Rep. 2024; 2(1):54.

PMID: 39516322 PMC: 11523999. DOI: 10.1038/s44276-024-00073-7.

Changes of circulating tumor cells expressing CD90 and EpCAM in early-phase of atezolizumab and bevacizumab for hepatocellular carcinoma.

Nosaka T, Murata Y, Akazawa Y, Takahashi K, Naito T, Matsuda H Heliyon. 2024; 10(14):e34441.

PMID: 39108869 PMC: 11301359. DOI: 10.1016/j.heliyon.2024.e34441.

Emerging Applications of Liquid Biopsies in Ovarian Cancer.

Chauhan U, Kohale M, Jaiswal N, Wankhade R Cureus. 2024; 15(12):e49880.

PMID: 38174205 PMC: 10762500. DOI: 10.7759/cureus.49880.

References

Kerachian M, Javadmanesh A, Azghandi M, Mojtabanezhad Shariatpanahi A, Yassi M, Shams Davodly E . Crosstalk between DNA methylation and gene expression in colorectal cancer, a potential plasma biomarker for tracing this tumor. Sci Rep. 2020; 10(1):2813. PMC: 7028731. DOI: 10.1038/s41598-020-59690-0. View

Chaudhuri A, Chabon J, Lovejoy A, Newman A, Stehr H, Azad T . Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. Cancer Discov. 2017; 7(12):1394-1403. PMC: 5895851. DOI: 10.1158/2159-8290.CD-17-0716. View

Ye M, Zheng X, Ye X, Zhang J, Huang C, Liu Z . Circulating Genetically Abnormal Cells Add Non-Invasive Diagnosis Value to Discriminate Lung Cancer in Patients With Pulmonary Nodules ≤10 mm. Front Oncol. 2021; 11:638223. PMC: 7991838. DOI: 10.3389/fonc.2021.638223. View

Tie J . Tailoring immunotherapy with liquid biopsy. Nat Cancer. 2022; 1(9):857-859. DOI: 10.1038/s43018-020-00113-4. View

Best M, Sol N, Kooi I, Tannous J, Westerman B, Rustenburg F . RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015; 28(5):666-676. PMC: 4644263. DOI: 10.1016/j.ccell.2015.09.018. View

Siravegna G, Marsoni S, Siena S, Bardelli A . Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol. 2017; 14(9):531-548. DOI: 10.1038/nrclinonc.2017.14. View

Forde P, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad M . Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022; 386(21):1973-1985. PMC: 9844511. DOI: 10.1056/NEJMoa2202170. View

Liang N, Li B, Jia Z, Wang C, Wu P, Zheng T . Ultrasensitive detection of circulating tumour DNA via deep methylation sequencing aided by machine learning. Nat Biomed Eng. 2021; 5(6):586-599. DOI: 10.1038/s41551-021-00746-5. View

Best M, Sol N, In t Veld S, Vancura A, Muller M, Niemeijer A . Swarm Intelligence-Enhanced Detection of Non-Small-Cell Lung Cancer Using Tumor-Educated Platelets. Cancer Cell. 2017; 32(2):238-252.e9. PMC: 6381325. DOI: 10.1016/j.ccell.2017.07.004. View

10.

Shen H, Jin Y, Zhao H, Wu M, Zhang K, Wei Z . Potential clinical utility of liquid biopsy in early-stage non-small cell lung cancer. BMC Med. 2022; 20(1):480. PMC: 9749360. DOI: 10.1186/s12916-022-02681-x. View

11.

Taniguchi H, Nakamura Y, Kotani D, Yukami H, Mishima S, Sawada K . CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 2021; 112(7):2915-2920. PMC: 8253296. DOI: 10.1111/cas.14926. View

12.

Martignano F, Munagala U, Crucitta S, Mingrino A, Semeraro R, Del Re M . Nanopore sequencing from liquid biopsy: analysis of copy number variations from cell-free DNA of lung cancer patients. Mol Cancer. 2021; 20(1):32. PMC: 7881593. DOI: 10.1186/s12943-021-01327-5. View

13.

Mishra A, Dubash T, Edd J, Jewett M, Garre S, Karabacak N . Ultrahigh-throughput magnetic sorting of large blood volumes for epitope-agnostic isolation of circulating tumor cells. Proc Natl Acad Sci U S A. 2020; 117(29):16839-16847. PMC: 7382214. DOI: 10.1073/pnas.2006388117. View

14.

Roy S, Kanda M, Nomura S, Zhu Z, Toiyama Y, Taketomi A . Diagnostic efficacy of circular RNAs as noninvasive, liquid biopsy biomarkers for early detection of gastric cancer. Mol Cancer. 2022; 21(1):42. PMC: 8826675. DOI: 10.1186/s12943-022-01527-7. View

15.

Chen L, Abou-Alfa G, Zheng B, Liu J, Bai J, Du L . Genome-scale profiling of circulating cell-free DNA signatures for early detection of hepatocellular carcinoma in cirrhotic patients. Cell Res. 2021; 31(5):589-592. PMC: 8089097. DOI: 10.1038/s41422-020-00457-7. View

16.

Jiang H, Chen X, Huang F, Xu X, Dong B, Luo J . Validation of a highly sensitive Sanger sequencing in detecting EGFR mutations from circulating tumor DNA in patients with lung cancers. Clin Chim Acta. 2022; 536:98-103. DOI: 10.1016/j.cca.2022.08.030. View

17.

Murtaza M, Dawson S, Tsui D, Gale D, Forshew T, Piskorz A . Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature. 2013; 497(7447):108-12. DOI: 10.1038/nature12065. View

18.

Roweth H, Battinelli E . Lessons to learn from tumor-educated platelets. Blood. 2021; 137(23):3174-3180. PMC: 8351883. DOI: 10.1182/blood.2019003976. View

19.

Chen K, Yang A, Carbone D, Kanu N, Liu K, Wang R . Spatiotemporal genomic analysis reveals distinct molecular features in recurrent stage I non-small cell lung cancers. Cell Rep. 2022; 40(2):111047. DOI: 10.1016/j.celrep.2022.111047. View

20.

Wang D, ORourke D, Sanchez-Garcia J, Cai T, Scheuenpflug J, Feng Z . Development of a liquid biopsy based purely quantitative digital droplet PCR assay for detection of MLH1 promoter methylation in colorectal cancer patients. BMC Cancer. 2021; 21(1):797. PMC: 8272385. DOI: 10.1186/s12885-021-08497-x. View